Innovative Signal Technology VivaQuant's proprietary MDSPTM technology offers highly accurate ECG measurements by eliminating 95% of noise, making it a valuable solution for research institutions, pharmaceutical companies, and medical device manufacturers seeking precise cardiac analysis tools.

Recent Product Launches The launch of the RX-1 mini and the AE-1010 software demonstrates VivaQuant's ongoing product innovation, presenting opportunities to target healthcare providers, research labs, and clinical trial organizations interested in advanced ECG analysis and portable cardiac monitoring solutions.

Industry Recognition & Patents Recognition as a finalist for the Tekne Awards and the award for US Patent No. 8,632,465 position VivaQuant as an industry leader in biomedical signal processing, appealing to partners and clients seeking cutting-edge technology and validated solutions.

Market Expansion Potential With a revenue range of 10 to 25 million dollars and targeted software products for cardiac rhythm research and arrhythmia detection, VivaQuant presents opportunities to expand into clinical research organizations, pharmaceutical trials, and digital health markets.

Strategic Partnerships & Funding VivaQuant’s focus on technological innovation and its recent awards suggest a readiness to collaborate with biotech firms, academic institutions, and technology partners to accelerate product adoption and market penetration in cardiac diagnostics.